To: Recipients of M100, 28th ed.

From: Jennifer K. Adams, MT(ASCP), MSHA
Vice President, Standards and Quality

Subject: Correction

This notification is to inform you of a correction made to CLSI document M100, *Performance Standards for Antimicrobial Susceptibility Testing*, 28th ed. The correction is described below and shown as highlighted and stricken text in the table excerpt.

Table 4A-2, Disk Diffusion QC Ranges for Nonfastidious Organisms and β-Lactam Combination Agents:

The disk content provided in Table 4A-2 for ceftazidime-avibactam is listed incorrectly as “30/15 µg.”

In Table 4A-2, the disk content for ceftazidime-avibactam has been corrected to read “30/20 µg.”

The Table 4A-2 correction is shown in the table excerpt below.

Table 4A-2. Disk Diffusion QC Ranges for Nonfastidious Organisms and β-Lactam Combination Agents

<table>
<thead>
<tr>
<th>QC Organisms and Characteristics</th>
<th>Escherichia coli ATCC® 25922</th>
<th>Pseudomonas aeruginosa ATCC® 27853</th>
<th>Staphylococcus aureus ATCC® 25923</th>
<th>Escherichia coli ATCC® 35218</th>
<th>Klebsiella pneumoniae ATCC® 700603®c</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antimicrobial Agent</td>
<td>B-lactamase negative</td>
<td>Inducible AmpC</td>
<td>B-lactamase negative, meCA negative</td>
<td>TEM-1</td>
<td>SHV-18 OXA-2 Mutations in OmpK35 and OmpK37 TEM-1</td>
</tr>
<tr>
<td>Ceftazidime-avibactam</td>
<td>30/15 µg</td>
<td>27-35</td>
<td>25-31</td>
<td>16-22</td>
<td>28-35</td>
</tr>
</tbody>
</table>

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service (customerservice@clsi.org).

We appreciate your commitment to CLSI and regret any inconvenience.